Actively Recruiting
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
Led by Children's Cancer Group, China · Updated on 2026-03-19
96
Participants Needed
1
Research Sites
789 weeks
Total Duration
On this page
Sponsors
C
Children's Cancer Group, China
Lead Sponsor
S
Shanghai Children's Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
Generally, pediatric patients tolerate acute toxicities but are vulnerable to late effects. Thus, increasing chemotherapy intensity to achieve more rapid complete early response to limit radiation therapy is worth testing. In this CCCG-HL-2024 study, Brentuximab vedotin (Bv) was used to replace VCR and bleomycin in the ABVE-PC regimen in the previous CCCG-HD-2018 study, respectively, to form a Bv-AEPC regimen for the treatment of newly diagnosed classic Hodgkin lymphoma (cHL) in children, adolescents and young adults. On the premise of maintaining a 4-year event free survival (EFS)\>90% in the low-, intermediate-and high-risk groups, increase the early assessment complete response rate (the overall early complete response rate increased by 20%, that is, from 54.0% to 74.0%) to further reduce the proportion of children receiving radiotherapy to benefit them.
CONDITIONS
Official Title
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 2 and less than 35 years at enrollment
- Newly diagnosed with classical Hodgkin lymphoma confirmed by at least two tertiary referral centers
- Adequate organ function
- Signed written informed consent by patient or legal guardian
You will not qualify if you...
- Diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma
- Pre-existing immunodeficiency such as primary immunodeficiency syndromes or organ transplant recipients
- Known HIV positive status
- Pregnant or lactating females planning to breastfeed
- Use of systemic corticosteroids within 28 days before enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Children's Medical Center
Shanghai, China
Actively Recruiting
Research Team
Y
YI JIN GAO, MD
CONTACT
J
JIE ZHAO
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here